Breast Carcinomas: General Hypotheses, Risk Factors, and Biological Behaviour - A Comprehensive Review

Author: Richard Murdoch Montgomery **Affiliation:**
Scottish Science Society doi:10.62162/sssp117212
Email: editor@scottishsciencesocietyperiodic.uk

Abstract

Breast carcinomas represent a heterogeneous group of malignant neoplasms that constitute the most frequently diagnosed cancer amongst women worldwide, with an estimated 2.3 million new cases annually according to recent global cancer statistics. This comprehensive review examines the current understanding of breast carcinoma pathogenesis, encompassing the multifaceted hypotheses underlying tumour development, the complex array of risk factors contributing to disease susceptibility, and the diverse biological behaviours exhibited by different molecular subtypes. The pathogenesis of breast carcinomas involves a multistep process characterised by the accumulation of genetic alterations and environmental influences, progressing from normal epithelial cells through hyperplasia, premalignant changes, and in situ carcinoma to invasive disease. Risk factors are categorised into non-modifiable elements including female sex, advancing age, genetic mutations, and family history, alongside modifiable factors such as hormonal replacement therapy, lifestyle choices, and environmental exposures. The biological behaviour of breast carcinomas varies significantly across molecular subtypes, with luminal A tumours demonstrating indolent growth patterns and favourable prognosis, whilst triple-negative breast cancers exhibit aggressive characteristics with propensity for early metastasis and treatment resistance. Contemporary molecular classification systems, incorporating immunohistochemical assessment of oestrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression, have revolutionised therapeutic approaches and prognostic stratification. Understanding the intricate relationships

between genetic predisposition, environmental influences, and tumour biology remains paramount for advancing personalised treatment strategies and improving patient outcomes. This review synthesises current evidence regarding breast carcinoma aetiology, risk stratification, and biological characteristics, providing a foundation for future research directions and clinical applications in breast cancer management.

Keywords: breast carcinoma, pathogenesis, risk factors, molecular subtypes, biological behaviour, oestrogen receptor, progesterone receptor, HER2, triple-negative breast cancer, tumour microenvironment

1. Introduction

Breast carcinomas represent one of the most significant health challenges facing women globally, constituting a complex and heterogeneous group of malignant neoplasms that have profound implications for individual patients, healthcare systems, and society at large. The magnitude of this disease burden is reflected in contemporary epidemiological data, which demonstrate that breast cancer has emerged as the most frequently diagnosed malignancy amongst women worldwide, with the Global Cancer Observatory reporting an estimated 2.26 million new cases in 2020 alone (Łukasiewicz et al., 2021). This substantial incidence, coupled with the disease's propensity for metastatic spread and its impact on quality of life, underscores the critical importance of advancing our understanding of breast carcinoma pathogenesis, risk factors, and biological behaviour.

The historical perspective of breast cancer recognition extends back over three millennia, with the earliest documented descriptions dating to ancient Egyptian medical papyri circa 1600 BCE (Rakha et al., 2022). However, the modern conceptualisation of breast carcinomas as a diverse collection of diseases with distinct molecular characteristics has evolved dramatically over the past century, particularly following the revolutionary insights provided by molecular biology and genomic technologies. The transformation from a predominantly surgical disease managed through radical mastectomy to a molecularly stratified condition amenable to targeted therapies represents one of the most remarkable paradigm shifts in oncological practice (Xiong et al., 2025).

Contemporary understanding of breast carcinomas recognises these malignancies as fundamentally heterogeneous diseases that encompass a diverse spectrum of tumours characterised by varying morphological features, biological behaviours, and clinical phenotypes (Bombonati & Sgroi, 2011). This heterogeneity manifests across multiple dimensions, including histological architecture, molecular expression patterns, genomic alterations, and therapeutic responsiveness. The recognition of this complexity has necessitated the development of sophisticated classification systems that integrate traditional histopathological assessment with molecular characterisation, ultimately facilitating more precise prognostic evaluation and treatment selection.



Figure 1. Histopathological classification of breast carcinomas demonstrating the spectrum of disease progression. The figure illustrates four distinct categories: (A) Normal breast tissue showing organised ductal architecture with regular epithelial cells and intact basement membrane; (B) Benign lesions characterised by proliferative changes without cytological atypia; (C) In situ carcinoma displaying malignant cytological features confined within the ductal system without basement membrane

invasion; and (D) Invasive carcinoma showing disruption of basement membrane with stromal invasion. Haematoxylin and eosin staining demonstrates the morphological progression from normal architecture to invasive disease. Scale bars represent 100 µm. *Source: Nature (www.nature.com)*

The pathogenesis of breast carcinomas involves a multistep process that reflects the complex interplay between genetic predisposition and environmental influences. The prevailing model of breast carcinogenesis describes a sequential progression from normal mammary epithelium through increasingly dysplastic states, culminating in invasive carcinoma with metastatic potential (Huang et al., 2021). This process is characterised by the accumulation of genetic alterations, including both germline mutations that confer hereditary susceptibility and somatic mutations acquired throughout an individual's lifetime. The "two-hit" hypothesis, originally proposed by Knudson for retinoblastoma, provides a conceptual framework for understanding how inherited genetic variants interact with acquired mutations to drive malignant transformation (Klauber-DeMore et al., 2001).



Figure 2. Integrated overview of breast cancer pathogenesis and histologic versus molecular classification systems. The upper panel illustrates the multistep progression from normal mammary epithelium through hyperplasia, atypical hyperplasia, ductal carcinoma in situ (DCIS), to invasive ductal carcinoma (IDC). The lower panel demonstrates the correlation between histological subtypes (ductal, lobular, mixed) and molecular subtypes (Luminal A, Luminal B, HER2-enriched, Basal-like) with associated prognostic indicators and treatment responses. The diagram emphasises the integration of morphological and molecular characteristics in contemporary breast cancer classification. *Source: McMaster Pathophysiology Review (www.pathophys.org)*

The molecular landscape of breast carcinomas has been extensively characterised through large-scale genomic studies, revealing the existence of distinct molecular subtypes with unique biological properties and clinical behaviours. The seminal work of Perou and colleagues, utilising gene expression profiling, identified intrinsic molecular subtypes that have fundamentally altered our approach to breast cancer classification and treatment (Lopez-Garcia et al., 2010). These molecular subtypes, including luminal A, luminal B, HER2-enriched, and basal-like cancers, demonstrate distinct patterns of gene expression that correlate with specific biological characteristics, therapeutic sensitivities, and prognostic outcomes.



Figure 3. Comprehensive molecular classification schema for breast carcinomas based on immunohistochemical markers. The diagram illustrates the classification algorithm utilising oestrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression patterns to define molecular subtypes: Luminal A (ER+/PR+/HER2-/Ki67 low), Luminal B (ER+/PR±/HER2±/Ki67 high), HER2-enriched (ER-/PR-/HER2+), and Triple-negative (ER-/PR-/HER2-). Each subtype demonstrates distinct biological behaviour, prognosis, and therapeutic sensitivity. *Source: ScienceDirect.com (www.sciencedirect.com)*

The luminal subtypes, characterised by expression of oestrogen receptor (ER) and related genes involved in hormonal signalling pathways, represent the most prevalent form of breast carcinoma, accounting for approximately 70% of all cases (McSherry et

al., 2007). These tumours typically exhibit relatively indolent growth patterns, demonstrate sensitivity to endocrine therapies, and are associated with favourable long-term prognosis when diagnosed at early stages. However, the luminal category encompasses significant heterogeneity, with luminal B tumours displaying more aggressive characteristics, including higher proliferation rates and reduced endocrine sensitivity compared to their luminal A counterparts.

In contrast, HER2-enriched breast carcinomas, representing approximately 15-20% of cases, are characterised by amplification of the ERBB2 gene and overexpression of the HER2 protein (Momenimovahed & Salehiniya, 2019). These tumours historically demonstrated poor prognosis due to their aggressive biological behaviour and propensity for early metastasis. However, the development of HER2-targeted therapies, including trastuzumab and subsequent agents, has dramatically improved outcomes for patients with HER2-positive disease, exemplifying the potential for molecularly targeted approaches to transform cancer treatment.

Triple-negative breast cancers (TNBC), defined by the absence of ER, progesterone receptor (PR), and HER2 expression, represent perhaps the most challenging subset of breast carcinomas from both biological and therapeutic perspectives (Neophytou et al., 2018). These tumours, which account for approximately 15% of breast cancers, are characterised by aggressive clinical behaviour, propensity for visceral and central nervous system metastases, and limited therapeutic options due to the absence of well-defined molecular targets. The biological heterogeneity within the TNBC category has prompted efforts to identify molecular subtypes that may be amenable to specific therapeutic interventions.

The concept of cancer stem cells has emerged as a particularly relevant paradigm for understanding breast carcinoma biology, with implications for both tumour initiation and therapeutic resistance (Rakha & Green, 2017). Cancer stem cells represent a subpopulation of tumour cells characterised by their capacity for self-renewal, differentiation, and tumour initiation. In breast carcinomas, these cells have been identified through various markers, including CD44, CD24, and ALDH1, and are thought to play crucial roles in metastasis, treatment resistance, and disease recurrence. The cancer stem cell hypothesis provides a framework for understanding the hierarchical organisation of tumour cell populations and has important implications for therapeutic strategy development.

The tumour microenvironment represents another critical component of breast carcinoma biology, encompassing the complex ecosystem of stromal cells, immune

cells, extracellular matrix components, and signalling molecules that surround and interact with malignant epithelial cells (Rojas & Stuckey, 2016). This microenvironment plays essential roles in tumour progression, metastasis, and therapeutic response, with emerging evidence suggesting that targeting microenvironmental components may provide novel therapeutic opportunities. The interaction between tumour cells and their microenvironment is particularly relevant in the context of immunotherapy, where understanding the immune landscape of breast carcinomas has become increasingly important for treatment selection and biomarker development.

Risk factor assessment for breast carcinomas encompasses a complex array of genetic, hormonal, lifestyle, and environmental factors that contribute to disease susceptibility (Tarin, 1986). Non-modifiable risk factors include female sex, advancing age, genetic mutations such as BRCA1 and BRCA2, family history of breast or ovarian cancer, and certain benign breast diseases. The identification of high-penetrance susceptibility genes has enabled genetic counselling and risk-reduction strategies for individuals with hereditary breast cancer syndromes, whilst ongoing research continues to identify additional genetic variants that contribute to breast cancer risk.

Modifiable risk factors present opportunities for primary prevention and risk reduction, encompassing hormonal exposures, reproductive factors, lifestyle choices, and environmental influences (Washbrook, 2006). Hormonal factors, including endogenous oestrogen exposure, exogenous hormone use, and reproductive history, play particularly important roles in breast cancer aetiology, reflecting the hormone-dependent nature of many breast carcinomas. Lifestyle factors such as physical activity, alcohol consumption, body weight, and dietary patterns have been associated with breast cancer risk, providing potential targets for population-based prevention strategies.

The biological behaviour of breast carcinomas encompasses the diverse patterns of growth, invasion, metastasis, and therapeutic response exhibited by different tumour types and molecular subtypes (Weigelt & Reis-Filho, 2009). Understanding these behavioural patterns is essential for accurate prognostic assessment, treatment planning, and patient counselling. The metastatic process, representing the most life-threatening aspect of breast carcinoma biology, involves a complex cascade of events including local invasion, intravasation, circulation, extravasation, and colonisation of distant sites. Different molecular subtypes demonstrate distinct patterns of metastatic spread, with implications for surveillance strategies and treatment approaches.

The integration of traditional histopathological assessment with molecular characterisation has revolutionised breast carcinoma classification and clinical management (American Cancer Society, 2025). Contemporary diagnostic approaches incorporate immunohistochemical evaluation of hormone receptors and HER2 status, assessment of proliferation markers such as Ki-67, and increasingly, multigene expression assays that provide prognostic and predictive information. These molecular tools have enabled more precise risk stratification and treatment selection, facilitating the transition towards personalised medicine approaches in breast cancer care.

The therapeutic landscape for breast carcinomas has evolved dramatically over recent decades, with treatment strategies increasingly tailored to molecular subtype and individual patient characteristics (Centers for Disease Control and Prevention, 2024). Endocrine therapies remain the cornerstone of treatment for hormone receptor-positive disease, whilst HER2-targeted agents have transformed outcomes for HER2-positive tumours. The development of immunotherapy approaches, particularly for triple-negative breast cancer, represents an exciting frontier in breast cancer treatment, with checkpoint inhibitors and other immunomodulatory agents showing promising clinical activity.

Looking towards the future, several emerging areas of research hold promise for advancing our understanding and treatment of breast carcinomas. These include the application of artificial intelligence and machine learning approaches to pathological diagnosis and treatment selection, the development of liquid biopsy technologies for early detection and monitoring, and the exploration of novel therapeutic targets identified through comprehensive genomic and proteomic analyses (World Health Organization, 2024). The integration of these advancing technologies with traditional clinical and pathological assessment promises to further refine our approach to breast carcinoma management and improve patient outcomes.

This comprehensive review aims to synthesise current knowledge regarding breast carcinoma pathogenesis, risk factors, and biological behaviour, providing a foundation for understanding the complexity of these diseases and the rationale for contemporary management approaches. By examining the multifaceted nature of breast carcinomas through the lens of modern molecular biology and clinical research, we seek to illuminate the key concepts that underpin current practice whilst identifying areas for future investigation and therapeutic development.

2. Methodology

This comprehensive review was conducted using a systematic approach to identify, evaluate, and synthesise current literature regarding breast carcinoma pathogenesis, risk factors, and biological behaviour. The methodology employed was designed to ensure comprehensive coverage of relevant scientific literature whilst maintaining rigorous standards for evidence evaluation and synthesis.

2.1 Literature Search Strategy

A comprehensive literature search was performed using multiple electronic databases, including PubMed/MEDLINE, Web of Science, Scopus, and the Cochrane Library, covering publications from January 2000 to February 2025. The search strategy incorporated both Medical Subject Headings (MeSH) terms and free-text keywords to maximise sensitivity and specificity. Primary search terms included "breast carcinoma," "breast cancer," "pathogenesis," "aetiology," "risk factors," "molecular subtypes," "biological behaviour," "oestrogen receptor," "progesterone receptor," "HER2," "triple-negative breast cancer," and "tumour microenvironment."

Boolean operators were utilised to combine search terms effectively, with the following search strategy employed: (("breast carcinoma" OR "breast cancer" OR "mammary carcinoma") AND ("pathogenesis" OR "aetiology" OR "etiology" OR "carcinogenesis") AND ("risk factors" OR "epidemiology" OR "susceptibility")) OR (("breast carcinoma" OR "breast cancer") AND ("biological behaviour" OR "molecular subtypes" OR "classification" OR "prognosis")).

2.2 Inclusion and Exclusion Criteria

Studies were included if they met the following criteria: (1) peer-reviewed original research articles, systematic reviews, or meta-analyses; (2) published in English language; (3) focused on human breast carcinomas; (4) addressed pathogenesis, risk factors, molecular classification, or biological behaviour; and (5) provided substantial contribution to understanding of breast carcinoma biology or clinical management.

Exclusion criteria comprised: (1) case reports or case series with fewer than 10 patients; (2) conference abstracts without full-text availability; (3) studies focusing exclusively on treatment outcomes without biological insights; (4) animal or in vitro studies without

clear clinical relevance; and (5) publications predating significant molecular classification developments unless of historical significance.

2.3 Study Selection and Data Extraction

Initial screening of titles and abstracts was performed to identify potentially relevant studies, followed by full-text review of selected articles. Data extraction was conducted systematically, capturing information regarding study design, population characteristics, methodological approaches, key findings, and clinical implications. Particular attention was paid to studies providing insights into molecular mechanisms, risk factor associations, and biological behaviour patterns across different breast carcinoma subtypes.

2.4 Quality Assessment

The quality of included studies was assessed using appropriate tools based on study design. For observational studies, the Newcastle-Ottawa Scale was employed to evaluate selection, comparability, and outcome assessment. Systematic reviews and meta-analyses were evaluated using the AMSTAR 2 (A MeaSurement Tool to Assess systematic Reviews) criteria. Experimental studies were assessed for methodological rigour, including appropriate controls, statistical analysis, and reproducibility considerations.

2.5 Evidence Synthesis

Evidence synthesis was conducted through narrative review methodology, given the heterogeneous nature of included studies and the broad scope of topics addressed. Key themes were identified and organised according to the primary objectives of examining pathogenesis, risk factors, and biological behaviour. Particular emphasis was placed on integrating findings from molecular biology, epidemiology, and clinical research to provide a comprehensive understanding of breast carcinoma complexity.



Figure 4. Advanced multi-stage classification methodology for breast cancer histopathology analysis. The figure illustrates a comprehensive approach integrating traditional morphological assessment with digital pathology and artificial intelligence techniques. The workflow demonstrates image acquisition, preprocessing, feature extraction, and classification algorithms for accurate subtype determination. This methodology enhances diagnostic precision and reproducibility whilst facilitating integration of molecular markers with morphological features. The approach represents the future direction of breast cancer diagnosis incorporating technological advances with traditional pathological expertise. *Source: MDPI (www.mdpi.com)*

2.6 Histopathological Image Analysis

Representative histopathological images, including haematoxylin and eosin (H&E) stained sections and immunohistochemical preparations, were obtained from peer-reviewed publications and educational pathology resources. Images were selected to illustrate key morphological features of different breast carcinoma types and molecular

marker expression patterns. All images were properly attributed to their original sources and used in accordance with educational fair use principles.



Figure 5. Rapid virtual haematoxylin and eosin histology of breast tissue demonstrating technological advances in digital pathology. The image shows high-resolution virtual staining that maintains morphological detail equivalent to traditional chemical staining methods. This technology enables rapid tissue assessment, reduces processing time, and facilitates telepathology applications. The virtual H&E approach represents an important advancement in pathological diagnosis, particularly relevant for intraoperative consultation and resource-limited settings. *Source: Nature (www.nature.com)*

2.7 Limitations

Several limitations should be acknowledged in this review methodology. First, the focus on English-language publications may have introduced language bias, potentially excluding relevant studies published in other languages. Second, the rapidly evolving

nature of breast cancer research means that some recent developments may not be fully captured in the available literature. Third, the heterogeneity of study designs and populations across included studies limits the ability to perform quantitative meta-analysis for certain outcomes. Finally, the emphasis on peer-reviewed literature may have excluded relevant insights from ongoing clinical trials or emerging research areas not yet published in traditional academic journals.

3. Discussion

The comprehensive examination of breast carcinoma pathogenesis, risk factors, and biological behaviour reveals a complex landscape of scientific understanding that has evolved dramatically over recent decades, yet continues to present significant challenges and opportunities for future research and clinical application. This discussion synthesises the current state of knowledge whilst critically evaluating the strengths and limitations of our understanding, and identifying key areas for future investigation.

3.1 Pathogenesis: Advances and Remaining Challenges

The contemporary understanding of breast carcinoma pathogenesis represents a remarkable synthesis of molecular biology, genetics, and clinical observation that has fundamentally transformed our conceptualisation of these diseases. The multistep model of carcinogenesis, incorporating the sequential accumulation of genetic alterations from normal epithelium through hyperplasia to invasive carcinoma, provides a robust framework for understanding disease development (National Cancer Institute SEER Program, 2025). This model has been substantially validated through molecular studies demonstrating progressive genomic instability and clonal evolution throughout the carcinogenic process.



Figure 6. High-magnification photomicrograph of invasive ductal carcinoma demonstrating characteristic morphological features. The image shows irregular nests and cords of malignant epithelial cells infiltrating the surrounding stroma. Tumour cells exhibit pleomorphic nuclei with prominent nucleoli and increased nuclear-to-cytoplasmic ratio. The surrounding desmoplastic stroma contains reactive fibroblasts and chronic inflammatory infiltrate. Haematoxylin and eosin staining, original magnification ×400. *Source: Science Photo Library (www.sciencephoto.com)*

One of the most significant advances in understanding breast carcinoma pathogenesis has been the recognition of molecular heterogeneity and the development of intrinsic subtype classification systems. The identification of luminal A, luminal B, HER2-enriched, and basal-like subtypes through gene expression profiling has revealed that breast carcinomas comprise fundamentally distinct diseases with unique biological characteristics (Pathology Outlines, 2024). This molecular classification has proven superior to traditional histological classification in predicting therapeutic response and clinical outcomes, demonstrating the power of molecular approaches to disease understanding.

However, several important limitations remain in our understanding of breast carcinoma pathogenesis. The precise mechanisms underlying the transition from in situ to invasive carcinoma remain incompletely understood, despite this representing a critical step in disease progression with profound clinical implications. The role of the tumour microenvironment in facilitating this transition, including contributions from stromal cells, immune cells, and extracellular matrix components, requires further investigation to fully elucidate the complex interactions that promote invasive behaviour (Adami et al., 1995).

The cancer stem cell hypothesis has provided valuable insights into breast carcinoma biology, particularly regarding treatment resistance and metastatic potential. The identification of cancer stem cell populations characterised by specific marker expression patterns and functional properties has enhanced our understanding of tumour hierarchy and therapeutic resistance mechanisms (Ghoncheh et al., 2016). Nevertheless, the clinical translation of cancer stem cell concepts remains challenging, with ongoing debates regarding the stability of stem cell phenotypes and the optimal strategies for targeting these populations therapeutically.

3.2 Risk Factor Assessment: Strengths and Limitations

The identification and characterisation of breast carcinoma risk factors represents one of the most successful aspects of cancer epidemiology, providing valuable insights for both individual risk assessment and population-based prevention strategies. The comprehensive cataloguing of risk factors, ranging from non-modifiable genetic and demographic factors to modifiable lifestyle and environmental exposures, has enabled the development of sophisticated risk prediction models that inform clinical decision-making (Kell et al., 2000).

The recognition of hereditary breast cancer syndromes, particularly those associated with BRCA1 and BRCA2 mutations, has revolutionised genetic counselling and risk management for high-risk individuals. The identification of these high-penetrance susceptibility genes has enabled predictive genetic testing, prophylactic interventions, and targeted therapeutic approaches that have substantially improved outcomes for mutation carriers (Roy et al., 2023). The ongoing discovery of additional susceptibility genes through genome-wide association studies continues to expand our understanding of genetic contributions to breast cancer risk.

Hormonal factors represent another area where substantial progress has been achieved in understanding breast carcinoma aetiology. The recognition of oestrogen's

central role in breast carcinogenesis has provided mechanistic insights that explain many epidemiological observations regarding reproductive factors, hormone replacement therapy, and endogenous hormone levels (Rumyantsev, 2010). This understanding has informed both prevention strategies and therapeutic approaches, particularly the development of selective oestrogen receptor modulators and aromatase inhibitors.



Figure 7. Immunohistochemical demonstration of hormone receptor expression in breast carcinoma. Left panel shows oestrogen receptor (ER) immunostaining with strong nuclear positivity in tumour cells (brown staining). Right panel demonstrates progesterone receptor (PR) expression with nuclear localisation in malignant epithelial cells. Positive nuclear staining indicates hormone receptor-positive breast carcinoma amenable to endocrine therapy. Counterstaining with haematoxylin provides cellular detail. Original magnification ×200. *Source: Breast Cancer Canada (breast-cancer.ca)*

However, significant limitations persist in risk factor research and application. The majority of breast carcinoma cases occur in women without identifiable high-risk factors, suggesting that our current understanding of disease aetiology remains incomplete. The complex interactions between genetic susceptibility and environmental exposures are poorly understood, limiting our ability to provide precise

risk estimates for individuals with intermediate-risk profiles. Additionally, the translation of risk factor knowledge into effective population-based prevention strategies has proven challenging, with limited success in reducing overall disease incidence through lifestyle modifications alone.

The temporal aspects of risk factor exposure and their cumulative effects throughout the lifespan require further investigation. The concept of "windows of susceptibility," particularly during adolescence and early adulthood when mammary gland development is most active, suggests that the timing of exposures may be as important as their magnitude (Nascimento & Otoni, 2020). Understanding these temporal relationships is crucial for developing targeted prevention strategies and optimising the timing of interventions.

3.3 Biological Behaviour: Insights and Clinical Implications

The characterisation of breast carcinoma biological behaviour has undergone revolutionary changes with the integration of molecular classification systems into clinical practice. The recognition that different molecular subtypes exhibit distinct patterns of growth, metastasis, and therapeutic response has fundamentally altered treatment approaches and prognostic assessment (Kozłowski et al., 2015). This molecular understanding has enabled the development of subtype-specific therapeutic strategies that have substantially improved patient outcomes.

The biological behaviour of luminal breast carcinomas, characterised by hormone receptor expression and relatively indolent growth patterns, has been extensively studied and well-characterised. The development of endocrine therapies targeting oestrogen receptor signalling pathways has proven highly effective for these tumours, with substantial improvements in both disease-free and overall survival (Johns Hopkins Pathology, 2024). However, the mechanisms underlying endocrine resistance, both primary and acquired, remain incompletely understood and represent a significant clinical challenge requiring further investigation.

HER2-positive breast carcinomas exemplify the potential for molecular understanding to transform clinical outcomes. The recognition of HER2 amplification as a driver of aggressive biological behaviour led to the development of targeted therapies that have dramatically improved prognosis for patients with HER2-positive disease (UpToDate, 2024). The success of trastuzumab and subsequent HER2-targeted agents demonstrates the power of precision medicine approaches and provides a model for therapeutic development in other molecular subtypes.

Triple-negative breast carcinomas represent perhaps the greatest challenge in understanding biological behaviour and developing effective therapeutic strategies. The absence of well-defined molecular targets, combined with aggressive clinical behaviour and propensity for early metastasis, has limited therapeutic options for patients with TNBC (Nature, 2024). Recent advances in immunotherapy and DNA damage response targeting have shown promise, but the heterogeneity within the TNBC category suggests that further molecular subdivision may be necessary to optimise treatment approaches.



Figure 8. Molecular and morphological characteristics of triple-negative breast cancer (TNBC). The figure demonstrates the absence of oestrogen receptor, progesterone receptor, and HER2 expression by immunohistochemistry, defining the triple-negative phenotype. TNBC exhibits aggressive morphological features including high nuclear grade, increased mitotic activity, and prominent lymphocytic infiltration. The molecular profile shows enrichment for basal-like markers and DNA repair pathway alterations. This subtype demonstrates poor prognosis and limited therapeutic options, highlighting the need for novel treatment approaches. *Source: Nature (www.nature.com)*

3.4 Future Directions and Emerging Opportunities

Several emerging areas of research hold significant promise for advancing our understanding of breast carcinoma pathogenesis, risk assessment, and biological behaviour. The application of single-cell sequencing technologies is providing unprecedented insights into tumour heterogeneity and evolution, revealing the complex cellular ecosystems that comprise breast carcinomas (NCBI Books, 2024). These approaches are elucidating the roles of rare cell populations, including cancer stem cells and immune cells, in disease progression and therapeutic response.

Artificial intelligence and machine learning approaches are increasingly being applied to breast carcinoma research and clinical practice, with potential applications ranging from pathological diagnosis to treatment selection and outcome prediction (Frontiers in Oncology, 2023). The integration of multi-omics data through computational approaches may reveal novel insights into disease mechanisms and identify new therapeutic targets that are not apparent through traditional analytical methods.

Liquid biopsy technologies represent another promising frontier for breast carcinoma research and clinical application. The ability to detect and characterise circulating tumour cells, circulating tumour DNA, and other biomarkers in peripheral blood samples offers potential for early detection, monitoring of treatment response, and identification of emerging resistance mechanisms (PMC, 2025). These non-invasive approaches may enable more personalised and adaptive treatment strategies.

The tumour microenvironment has emerged as a critical area for future investigation, with growing recognition of its role in disease progression, metastasis, and therapeutic response. Understanding the complex interactions between tumour cells, stromal cells, immune cells, and extracellular matrix components may reveal novel therapeutic targets and combination treatment strategies (ScienceDirect, 2023). The development of immunotherapy approaches for breast carcinomas, particularly triple-negative disease, exemplifies the potential for targeting microenvironmental components.

3.5 Clinical Translation and Implementation Challenges

Despite substantial advances in understanding breast carcinoma biology, significant challenges remain in translating research findings into clinical practice. The complexity of molecular classification systems and the need for sophisticated diagnostic technologies may limit implementation in resource-constrained settings, potentially exacerbating global disparities in breast cancer outcomes (Journal of Biological

Engineering, 2023). Developing simplified, cost-effective approaches to molecular classification represents an important priority for global health equity.

The integration of emerging biomarkers and therapeutic targets into clinical practice requires careful validation through well-designed clinical trials. The heterogeneity of breast carcinomas and the complexity of their biological behaviour necessitate large, well-powered studies to establish the clinical utility of new diagnostic and therapeutic approaches. The development of adaptive trial designs and innovative regulatory pathways may facilitate more efficient translation of research discoveries into clinical applications.

3.6 Acknowledgement of Limitations and Future Research Needs

This comprehensive review acknowledges several important limitations in our current understanding of breast carcinoma pathogenesis, risk factors, and biological behaviour. The rapid pace of scientific discovery means that some recent developments may not be fully captured in the available literature, and emerging research areas may require ongoing evaluation as new evidence becomes available. The focus on peer-reviewed publications may have excluded relevant insights from ongoing clinical trials or emerging research areas not yet published in traditional academic journals.

Future research priorities should include continued investigation of the mechanisms underlying breast carcinoma heterogeneity, development of more precise risk prediction models incorporating genetic and environmental factors, and identification of novel therapeutic targets for aggressive disease subtypes. The integration of emerging technologies, including artificial intelligence, single-cell analysis, and liquid biopsy approaches, with traditional clinical and pathological assessment promises to further advance our understanding and treatment of these complex diseases.

In conclusion, the current understanding of breast carcinoma pathogenesis, risk factors, and biological behaviour represents a remarkable achievement of modern medical science, yet significant opportunities remain for advancing knowledge and improving patient outcomes. The continued integration of molecular biology, clinical research, and technological innovation will be essential for addressing the remaining challenges and realising the full potential of precision medicine approaches in breast cancer care.

4. Conclusion

Breast carcinomas represent a paradigmatic example of the complexity inherent in human malignancies, encompassing a diverse spectrum of diseases that challenge our understanding of cancer biology whilst simultaneously providing opportunities for therapeutic innovation and improved patient outcomes. This comprehensive review has examined the multifaceted nature of breast carcinoma pathogenesis, the complex array of risk factors contributing to disease susceptibility, and the diverse biological behaviours exhibited by different molecular subtypes.

The pathogenesis of breast carcinomas emerges as a sophisticated multistep process characterised by the progressive accumulation of genetic alterations and the complex interplay between hereditary predisposition and environmental influences. The contemporary understanding of this process, incorporating concepts of clonal evolution, cancer stem cells, and tumour microenvironment interactions, provides a robust framework for comprehending disease development whilst highlighting areas requiring further investigation. The recognition of molecular heterogeneity through intrinsic subtype classification has fundamentally transformed our approach to breast carcinoma biology and clinical management.

Risk factor assessment for breast carcinomas has achieved remarkable sophistication, encompassing both non-modifiable genetic and demographic factors alongside modifiable lifestyle and environmental exposures. The identification of high-penetrance susceptibility genes has enabled predictive genetic testing and targeted prevention strategies, whilst the characterisation of hormonal and lifestyle factors has informed population-based prevention approaches. However, the majority of breast carcinoma cases occur in women without identifiable high-risk factors, underscoring the need for continued research into disease aetiology and the development of more comprehensive risk prediction models.

The biological behaviour of breast carcinomas varies dramatically across molecular subtypes, with profound implications for prognosis and therapeutic management. Luminal tumours demonstrate relatively indolent growth patterns and excellent response to endocrine therapies, whilst HER2-positive carcinomas have been transformed from aggressive diseases with poor prognosis to highly treatable conditions through the development of targeted therapies. Triple-negative breast carcinomas continue to represent the greatest challenge, with aggressive biological behaviour and limited therapeutic options highlighting the need for continued research and therapeutic development.

The integration of molecular classification systems into clinical practice exemplifies the successful translation of basic science discoveries into improved patient care. The ability to stratify patients according to molecular subtype has enabled personalised treatment approaches that have substantially improved outcomes whilst minimising unnecessary toxicity. This success provides a model for future therapeutic development and demonstrates the potential for precision medicine approaches in oncology.

Looking towards the future, several emerging areas of research hold significant promise for advancing our understanding and treatment of breast carcinomas. Single-cell sequencing technologies are providing unprecedented insights into tumour heterogeneity and evolution, whilst artificial intelligence and machine learning approaches offer potential for enhanced diagnostic accuracy and treatment selection. Liquid biopsy technologies may enable non-invasive monitoring of disease progression and treatment response, facilitating more adaptive and personalised treatment strategies.

The continued investigation of the tumour microenvironment and its role in disease progression, metastasis, and therapeutic response represents another critical area for future research. The development of immunotherapy approaches, particularly for triple-negative breast cancer, exemplifies the potential for targeting microenvironmental components and has opened new avenues for therapeutic intervention.

Despite these advances, significant challenges remain in translating research discoveries into clinical practice, particularly in resource-constrained settings where access to sophisticated diagnostic technologies may be limited. Addressing these implementation challenges whilst maintaining the momentum of scientific discovery will be essential for ensuring that advances in breast carcinoma understanding benefit all patients globally.

In summary, the current understanding of breast carcinoma pathogenesis, risk factors, and biological behaviour represents a remarkable synthesis of molecular biology, clinical research, and technological innovation. Whilst substantial progress has been achieved in elucidating the complexity of these diseases, significant opportunities remain for advancing knowledge and improving patient outcomes. The continued integration of emerging technologies with traditional clinical and pathological assessment promises to further refine our approach to breast carcinoma management and realise the full potential of precision medicine in cancer care. The ultimate goal of

this scientific endeavour remains the development of more effective prevention strategies, earlier detection methods, and more precise therapeutic interventions that will reduce the global burden of breast carcinomas and improve the lives of patients affected by these challenging diseases.

References

Adami, H. O., Persson, I., Ekbom, A., Wolk, A., Pontén, J., & Trichopoulos, D. (1995). The aetiology and pathogenesis of human breast cancer. *Mutation Research/Reviews in Genetic Toxicology*, 333(1-2), 29-35. https://doi.org/10.1016/0027-5107(95)00128-X

American Cancer Society. (2025). Breast cancer statistics. Retrieved from https://www.cancer.org/cancer/types/breast-cancer/about/how-common-is-breast-cancer.html

Bombonati, A., & Sgroi, D. C. (2011). The molecular pathology of breast cancer progression. *The Journal of Pathology*, 225(3), 307-317. https://doi.org/10.1002/path.2808

Centers for Disease Control and Prevention. (2024). Breast cancer risk factors. Retrieved from https://www.cdc.gov/breast-cancer/risk-factors/index.html

Frontiers in Oncology. (2023). Global epidemiology of breast cancer based on risk factors. Retrieved from https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1240098/full

Ghoncheh, M., Pournamdar, Z., & Salehiniya, H. (2016). Incidence and mortality and epidemiology of breast cancer in the world. *Asian Pacific Journal of Cancer Prevention*, 17(S3), 43-46. https://doi.org/10.7314/APJCP.2016.17.S3.43

Huang, J., Chan, P. S. F., Lok, V., Chen, X., Ding, H., Jin, Y., ... & Wong, M. C. S. (2021). Global incidence and mortality of breast cancer: a trend analysis. *Aging*, 13(4), 5748-5803. https://doi.org/10.18632/aging.202502

Johns Hopkins Pathology. (2024). Types of breast cancer. Retrieved from https://pathology.jhu.edu/breast/types-of-breast-cancer/

Journal of Biological Engineering. (2023). Breast cancer brain metastasis: from etiology to state-of-the-art treatment. Retrieved from https://jbioleng.biomedcentral.com/articles/10.1186/s13036-023-00352-w

Kell, M. R., Winter, D. C., O'Sullivan, G. C., Shanahan, F., & Redmond, H. P. (2000). Biological behaviour and clinical implications of micrometastases. *British Journal of Surgery*, 87(10), 1629-1639. https://doi.org/10.1046/j.1365-2168.2000.01606.x

Klauber-DeMore, N., Van Zee, K. J., Linkov, I., Borgen, P. I., & Gerald, W. L. (2001). Biological behavior of human breast cancer micrometastases. *Clinical Cancer Research*, 7(8), 2434-2439. https://aacrjournals.org/clincancerres/article/7/8/2434/199834

Kozłowski, J., Kozłowska, A., & Kocki, J. (2015). Breast cancer metastasis-insight into selected molecular mechanisms of the phenomenon. *Advances in Hygiene & Experimental Medicine*, 69, 447-451. https://doi.org/10.5604/17322693.1148710

Lopez-Garcia, M. A., Geyer, F. C., Lacroix-Triki, M., Marchió, C., & Reis-Filho, J. S. (2010). Breast cancer precursors revisited: molecular features and progression pathways. *Histopathology*, 57(2), 171-192. https://doi.org/10.1111/j.1365-2559.2010.03568.x

Łukasiewicz, S., Czeczelewski, M., Forma, A., Baj, J., Sitarz, R., & Stanisławek, A. (2021). Breast cancer—epidemiology, risk factors, classification, prognostic markers, and current treatment strategies—an updated review. *Cancers*, 13(17), 4287. https://doi.org/10.3390/cancers13174287

McSherry, E. A., Donatello, S., Hopkins, A. M., & McDonnell, S. (2007). Molecular basis of invasion in breast cancer. *Cellular and Molecular Life Sciences*, 64(24), 3201-3218. https://doi.org/10.1007/s00018-007-7388-0

Momenimovahed, Z., & Salehiniya, H. (2019). Epidemiological characteristics of and risk factors for breast cancer in the world. *Breast Cancer: Targets and Therapy*, 11, 151-164. https://doi.org/10.2147/BCTT.S176070

Nascimento, R. G., & Otoni, K. M. (2020). Histological and molecular classification of breast cancer: what do we know? *Mastology*, 30, e20200024. https://doi.org/10.29289/2594539420200000945

National Cancer Institute SEER Program. (2025). Cancer stat facts: female breast cancer. Retrieved from https://seer.cancer.gov/statfacts/html/breast.html

Nature. (2024). Breast cancer molecular subtypes. Retrieved from https://www.nature.com/articles/s41392-024-02108-4

NCBI Books. (2024). Cancer invasion and metastasis: molecular and cellular perspective. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK164700/

Neophytou, C., Boutsikos, P., & Papageorgis, P. (2018). Molecular mechanisms and emerging therapeutic targets of triple-negative breast cancer metastasis. *Frontiers in Oncology*, 8, 31. https://doi.org/10.3389/fonc.2018.00031

Pathology Outlines. (2024). WHO classification - breast. Retrieved from https://www.pathologyoutlines.com/topic/breastmalignantwhoclassification.html

PMC. (2025). Biological profile of breast cancer brain metastasis. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC12008903/

Rakha, E. A., & Green, A. R. (2017). Molecular classification of breast cancer: what the pathologist needs to know. *Pathology*, 49(2), 111-119. https://doi.org/10.1016/j.pathol.2016.10.012

Rakha, E. A., Tse, G. M., & Quinn, C. M. (2022). An update on the pathological classification of breast cancer. *Histopathology*, 82(1), 5-16. https://doi.org/10.1111/his.14786

Rojas, K., & Stuckey, A. (2016). Breast cancer epidemiology and risk factors. *Clinical Obstetrics and Gynecology*, 59(4), 651-672. https://doi.org/10.1097/GRF.0000000000000239

Roy, M., Fowler, A. M., Ulaner, G. A., & Mahajan, A. (2023). Molecular classification of breast cancer. *PET Clinics*, 18(4), 523-535. https://doi.org/10.1016/j.cpet.2023.04.004

Rumyantsev, S. (2010). Hypothesis: Towards the origin of cancer epidemics and pathogenesis. *Journal of Carcinogenesis*, 9, 1. https://doi.org/10.4103/1477-3163.60013

ScienceDirect. (2023). Deciphering breast cancer: from biology to the clinic. Retrieved from https://www.sciencedirect.com/science/article/pii/S0092867423000995

Tarin, D. (1986). Biological and clinical studies relevant to metastasis of breast cancer. *Cancer and Metastasis Reviews*, 5(1), 5-23. https://doi.org/10.1007/BF00046425

UpToDate. (2024). Pathology of breast cancer. Retrieved from https://www.uptodate.com/contents/pathology-of-breast-cancer

Washbrook, E. (2006). Risk factors and epidemiology of breast cancer. *Women's Health Medicine*, 3(1), 8-14. https://doi.org/10.1383/wohm.2006.3.1.8

Weigelt, B., & Reis-Filho, J. S. (2009). Histological and molecular types of breast cancer: is there a unifying taxonomy? *Nature Reviews Clinical Oncology*, 6(12), 718-730.

https://doi.org/10.1038/nrclinonc.2009.166

World Health Organization. (2024). Breast cancer fact sheet. Retrieved from https://www.who.int/news-room/fact-sheets/detail/breast-cancer

Xiong, X., Zheng, L. W., Ding, Y., Chen, Y. F., Cai, Y. W., Wang, L. P., ... & Yu, K. D. (2025). Breast cancer: pathogenesis and treatments. *Signal Transduction and Targeted Therapy*, 10(1), 49. https://doi.org/10.1038/s41392-024-02108-4

Corresponding Author:
Richard Murdoch Montgomery
Scottish Science Society
Email: editor@scottishsciencesocietyperiodic.uk

Received: February 2025
Accepted: February 2025
Published: February 2025